指南与共识外周动脉疾病

间歇性跛行血管内治疗未达SVS疗效指南最低标准

Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines.
指南 / 共识 · J Vasc Surg · 2020-11-27

本研究基于Vascular Quality Initiative数据,纳入2004至2017年间16,152例因间歇性跛行接受外周血管介入且随访超过9个月的患者,评估其跛行复发和2年内再次手术情况。结果显示仅32%的患者2年内无跛行复发,多数未达到SVS指南要求的2年无复发症状>50%的标准,且斑块旋切术和多支血管治疗与不良结局相关。

要点

  • 仅32%患者2年内无跛行复发,未达SVS指南>50%的标准。
  • 斑块旋切术和多支血管治疗与跛行复发及再次手术风险增加相关。
  • 出院时使用抗血小板和他汀类药物与更长的无复发时间相关。

核心结论

  • 多数因间歇性跛行接受血管内治疗的患者未达到SVS指南关于2年无复发症状>50%的长期疗效标准。
  • 斑块旋切术和多支血管治疗与较差的长期结局相关。

研究设计与样本

  • 回顾性队列研究,纳入Vascular Quality Initiative数据库中2004至2017年因间歇性跛行接受外周血管介入、数据完整且随访>9个月的患者,共16,152例,平均年龄66岁。

主要发现

  • 2年无跛行复发生存率为32%,无再次手术生存率为76%。
  • 治疗超过两支动脉与跛行复发风险增加相关(HR 1.19;95%CI 1.09-1.31)及再次手术风险增加相关(HR 1.25;95%CI 1.09-1.45)。
  • 使用斑块旋切术与跛行复发风险增加相关(HR 1.29;95%CI 1.08-1.33)及再次手术风险增加相关(HR 1.31;95%CI 1.13-1.52)。
  • 出院时使用抗血小板和他汀类药物与跛行复发风险降低相关(HR 0.84;95%CI 0.78-0.91)及再次手术风险降低相关(HR 0.77;95%CI 0.69-0.87)。
  • 按解剖部位分层,2年无跛行复发率:孤立主髂动脉介入37%,主髂及股腘动脉介入22%,孤立股腘动脉介入30%,股腘及胫动脉介入20%。

关键数值与推荐

  • SVS指南要求间歇性跛行血管内治疗后2年无复发症状>50%,本研究仅32%患者达到。
  • 45%患者为当前吸烟者,28%出院时未使用抗血小板或他汀类药物。

临床怎么用

  • 术前应优化药物治疗,包括抗血小板和他汀类药物。
  • 应谨慎选择斑块旋切术和多支血管治疗,并告知患者长期结局较差的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Because the treatment of intermittent claudication (IC) is elective, good short- and long-term outcomes are imperative. The objective of the present study was to examine the outcomes of endovascular management of IC reported in the Vascular Quality Initiative and compare them with the Society for Vascular Surgery guidelines for IC treatment to determine whether real-world results are within the guidelines. METHODS: Patients undergoing peripheral vascular intervention for IC from 2004 to 2017 with complete data and >9 month follow-up were included. The primary outcome measures were IC recurrence and repeat procedures performed ≤2 years after the initial treatment. RESULTS: A total of 16,152 patients met the inclusion criteria, with a mean age of 66 years. Of the 16,152 patients, 61% were men, 45% were current smokers, and 28% had been discharged without antiplatelet or statin medication. Adjusted analyses revealed that treatment of more than two arteries was associated with a shorter time to IC recurrence (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.09-1.31) and a shorter time to repeat procedures (HR, 1.25; 95% CI, 1.09-1.45). The use of atherectomy was also associated with a shorter time to IC recurrence (HR, 1.29; 95% CI, 1.08-1.33) and a shorter time to repeat procedures (HR, 1.31; 95% CI, 1.13-1.52). Discharge with antiplatelet and statin medications was associated with a longer time to IC recurrence (HR, 0.84; 95% CI, 0.78-0.91) and a longer time to repeat procedures (HR, 0.77; 95% CI, 0.69-0.87). Life-table analysis at 2 years revealed that only 32% of patients were free from IC recurrence, although 76% had not undergone repeat procedures. Stratified by anatomic treatment level, 37% of isolated aortoiliac interventions, 22% of aortoiliac and femoropopliteal interventions, 30% of isolated femoropopliteal interventions, and 20% of femoropopliteal and tibial interventions had remained free from IC recurrence at 2 years. CONCLUSIONS: Most patients treated with an endovascular approach to IC did not meet the Society for Vascular Surgery guidelines for long-term freedom from recurrent symptoms of >50% at 2 years. Many lacked preprocedure optimization of medical management. The use of atherectomy and treatment of more than two arteries were associated with poor outcomes after peripheral vascular intervention for IC, because only 32% of these patients were free from recurrent symptoms at 2 years. Even when risk factor modification is optimized before the procedure, vascular specialists should be aware of the association between atherectomy and multivessel interventions with poorer long-term outcomes and counsel patients appropriately before intervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bath J, Lawrence PF, Neal D, et al. Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines. J Vasc Surg. 2020. PMID: 33253869. doi:10.1016/j.jvs.2020.10.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。